|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
ATE87659T1
(de)
|
1986-09-02 |
1993-04-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5236940A
(en)
|
1988-12-15 |
1993-08-17 |
Rhone-Poulenc Sante |
Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
|
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US7208517B1
(en)
|
1994-08-19 |
2007-04-24 |
Abbott Labortories |
Endothelin antagonists
|
|
US7365093B2
(en)
|
1994-08-19 |
2008-04-29 |
Abbott Laboratories |
Endothelin antagonists
|
|
US6946481B1
(en)
|
1994-08-19 |
2005-09-20 |
Abbott Laboratories |
Endothelin antagonists
|
|
US20020062121A1
(en)
|
1995-05-16 |
2002-05-23 |
Karl Tryggvason |
Perfusion apparatus and methods for pharmaceutical delivery
|
|
ES2259803T3
(es)
|
1996-02-13 |
2006-10-16 |
Abbott Laboratories |
Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
|
|
US20040191774A1
(en)
|
2001-09-11 |
2004-09-30 |
Moskowitz David W |
Endothelin-1 promoter polymorphism
|
|
WO2003080038A1
(en)
|
2002-03-22 |
2003-10-02 |
Kissei Pharmaceutical Co., Ltd. |
Preventive or therapeutic agent for kidney disease
|
|
AU2003226356A1
(en)
|
2002-04-12 |
2003-10-27 |
Ramot At Tel Aviv University Ltd. |
Prevention of brain inflammation as a result of induced autoimmune response
|
|
US20030229906A1
(en)
|
2002-04-15 |
2003-12-11 |
Gelman Irwin H. |
Methods and compositions for the treatment of disorders of HIV infection
|
|
US9388427B2
(en)
|
2002-12-02 |
2016-07-12 |
Biovec, Llc |
In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
|
|
US7410483B2
(en)
|
2003-05-23 |
2008-08-12 |
Novare Surgical Systems, Inc. |
Hand-actuated device for remote manipulation of a grasping tool
|
|
DE602005022871D1
(de)
|
2004-06-07 |
2010-09-23 |
Univ Ramot |
Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
|
|
WO2006034234A1
(en)
|
2004-09-17 |
2006-03-30 |
Abbott Laboratories |
Crystalline form 3 of atrasentan hydrochloride
|
|
WO2006034085A1
(en)
|
2004-09-17 |
2006-03-30 |
Abbott Laboratories |
Crystalline form of atrasentan hydrochloride
|
|
WO2006034094A1
(en)
|
2004-09-17 |
2006-03-30 |
Abbott Laboratories |
Crystalline form 1 of atrasentan hxdrochloride
|
|
CA2578824A1
(en)
|
2004-09-17 |
2006-03-30 |
Abbott Laboratories |
Crystalline form 2 of atrasentan hydrochloride
|
|
US8231907B2
(en)
|
2006-03-21 |
2012-07-31 |
Morehouse School Of Medicine |
Nanoparticles for delivery of active agents
|
|
AU2007230580A1
(en)
*
|
2006-03-27 |
2007-10-04 |
Genentech, Inc. |
Methods for treating kidney disorders
|
|
WO2007119214A2
(en)
|
2006-04-13 |
2007-10-25 |
Actelion Pharmaceuticals Ltd |
Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
|
|
NZ578164A
(en)
|
2007-01-16 |
2011-12-22 |
Musc Found For Res Dev |
Compositions and methods for diagnosing, treating, and preventing prostate conditions
|
|
AU2008282773B8
(en)
|
2007-07-31 |
2013-03-07 |
Gilead Sciences, Inc. |
Metabolites and derivatives of ambrisentan
|
|
EP2545920A1
(en)
|
2007-08-22 |
2013-01-16 |
Abbott GmbH & Co. KG |
Therapy for complications of diabetes
|
|
US20120083421A1
(en)
|
2008-10-16 |
2012-04-05 |
The Trustees Of Columbia University In The City Of New York |
Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
|
|
EP3708163A1
(en)
|
2009-03-31 |
2020-09-16 |
Ligand Pharmaceuticals, Inc. |
Use of sparsentan for the treatment of chronic inflammatory diseases
|
|
EP2509594A1
(en)
|
2009-12-09 |
2012-10-17 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
|
|
US9255931B2
(en)
|
2010-06-24 |
2016-02-09 |
Morehouse School Of Medicine |
Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
|
|
US9365445B2
(en)
|
2010-07-28 |
2016-06-14 |
Nippon Electric Glass Co., Ltd. |
Method for producing phosphor-encapsulating capillary tube, phosphor-encapsulating capillary tube, wavelength-converting member, and method for producing wavelength-converting member
|
|
US20160015701A1
(en)
*
|
2013-03-08 |
2016-01-21 |
Abbive Inc. |
Methods of Treating Acute Kidney Injury
|
|
KR20160003128A
(ko)
|
2013-04-30 |
2016-01-08 |
애브비 인코포레이티드 |
아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
|
|
CA2916033C
(en)
*
|
2013-07-08 |
2022-08-23 |
Abbvie Inc. |
Stabilized pharmaceutical dosage forms comprising atrasentan
|
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
|
JP2017534634A
(ja)
*
|
2014-11-07 |
2017-11-24 |
アッヴィ・インコーポレイテッド |
体液貯留の予測因子を使用してｃｋｄを処置する方法
|
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
|
US20170014386A1
(en)
|
2015-07-16 |
2017-01-19 |
Abbvie, Inc. |
Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
|
|
MA43260A
(fr)
*
|
2015-11-18 |
2018-09-26 |
Merck Sharp & Dohme |
Liants pd1 et/ou lag3
|
|
US10736960B2
(en)
|
2016-01-05 |
2020-08-11 |
Omeros Corporation |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
JP2019530713A
(ja)
*
|
2016-10-13 |
2019-10-24 |
レトロフィン， インコーポレイテッド |
腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
|
|
MX2021014356A
(es)
|
2016-11-23 |
2022-11-24 |
Chemocentryx Inc |
Metodo para tratar glomeruloesclerosis segmentaria focal.
|
|
AU2018347361A1
(en)
|
2017-10-11 |
2020-04-30 |
Chemocentryx, Inc. |
Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
|
|
KR20260037123A
(ko)
|
2017-11-30 |
2026-03-17 |
이도르시아 파마슈티컬스 리미티드 |
엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
|
|
KR20230015874A
(ko)
*
|
2019-12-17 |
2023-01-31 |
치누크 세라퓨틱스, 인크. |
아트라센탄에 의해 iga 신장병증을 치료하는 방법
|
|
US20220304979A1
(en)
|
2019-12-17 |
2022-09-29 |
Chinook Therapeutics, Inc. |
Methods of reducing disease flares
|
|
JP2023521169A
(ja)
|
2020-04-10 |
2023-05-23 |
チヌーク セラピューティクス，インコーポレイテッド |
糖尿病性腎疾患の処置方法
|
|
US20220243994A1
(en)
|
2021-02-04 |
2022-08-04 |
Northrop Grumman Systems Corporation |
Metal woodpile capillary wick
|